Deb Maskens

@debmaskens.bsky.social

Cancer patient advocate. Canadian. Interested in patient involvement in cancer research, evidence-based advocacy, shared decision making globally. #cansky #oncsky #kcsm #kidneycancer #shareddecisionmaking

If ever there was a call for patient preference, this would be it. Lack of such data for FDA is no reason not to collect real-world patient experience data now. As a pt currently on IV pembrolizumab, I would give my right arm for subq alternative. 100%.

OncLive@onclive.bsky.social · 3w ago

The integration of subcutaneous pembrolizumab into practice has raised cost and convenience questions, according to Laure-Anne Teuwen, MD, PhD. Read more on her perspectives here #oncology www.onclive.com/view/subcuta...

I've been following this cyclospora outbreak story (and writing for Forbes) and now would be a good time to stop eating any uncooked fresh produce from the U.S. The CDC are investigating but no source/s identified yet. Canadian fresh produce is a much better bet. Never a better time to buy Canadian

What does “optimal” SDM look like? 💡 Our network, the Global Cancer Coalitions Network (GCCN), sets out 3 core elements in its new infographic: clinical evidence and expertise, patient preferences and goals, and biological, psychological and social context, (1/2)

Bild

@care1project.bsky.social A great pragmatic trial that will improve the capturing of real world patient experience using ePROs, and advanced and more relevant #QoL measurements. #kidneycancer #wkcd

International Kidney Cancer Coalition@ikccorg.bsky.social · 2mo ago

#ResearchInitiativesHighlight: For World Kidney Cancer Day 2026, IKCC wishes to highlight the CARE1 European project. This Pragmatic Clinical Trial is a European phase III multi-centre study of first-line treatment for metastatic kidney cancer. (1/4)

Looking forward to expert discussion on RAMPART. Interesting that monotherapy arm was negative. Side effects significant in double immunotherapy, but no meaningful difference in Qol? Note: 3 grade 5 events (deaths)in Adjuvant setting. #kidneycancer #kcsm #ASCO26

OncLive@onclive.bsky.social · 2mo ago

🏥 #ASCO26 update in kidney cancer: Adjuvant durvalumab + tremelimumab demonstrated a disease-free survival advantage vs active monitoring in patients with resected RCC, although durvalumab monotherapy did not. @ascocancer.bsky.social #RCC #kcsm #oncology Read more: www.onclive.com/view/adjuvan...

Abstract looks good for #kidneycancer patients. @theaacr.bsky.social @elizsmckenna.bsky.social Any way for patient advocates to access please?

Elizabeth McKenna@elizsmckenna.bsky.social · 3mo ago

Now online in Cancer Discovery @aacrjournals.bsky.social: [18F]RCCB6 PET/CT in Diagnosing ccRCC: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging - by Qianyun Wu, Shuxian An, Arturo Chiti, Gang Huang, Jianjun Liu, Weijun Wei, ad colleagues doi.org/10.1158/2159...